C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics

Earlier this year, Windhover Information's The RPM Report called the C-Path Institute "the showcase effort to turn the Food and Drug Administration's promising rhetoric about improving drug development into useful procedures." (See "A Critical Test for FDA's Critical Path Initiative," The RPM Report, February 2006 Also see "A Critical Test for FDA's Critical Path Initiative" - Pink Sheet, 1 February, 2006..) In addition to the early programs outlined in that article, C-Path is now engaging more than 20 pharma and diagnostics companies with interests in non-small-cell lung cancer (NSCLC) treatment using EGF receptor (EGFr)-targeted drugs and diagnostics.

This proposed initiative could forge a template for future companion reviews of drugs and diagnostics, and further address the issue...